Infliximab for Acute Kidney Injury

This trial tests a new treatment for individuals with acute kidney injury (AKI) caused by immune checkpoint inhibitors, drugs used in cancer therapy. Researchers aim to determine if adding infliximab, a medication that reduces inflammation, to standard prednisone treatment can accelerate kidney recovery. Eligible participants should have experienced a significant increase in kidney issues after receiving immune checkpoint treatments within the last six months. As a Phase 4 trial, this research seeks to understand how the already FDA-approved and effective treatment can benefit more patients.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are taking high-dose glucocorticoids or other immunosuppressants within 14 days before screening.

Infliximab has been studied for safety in various conditions and is FDA-approved for treating autoimmune diseases like Crohn's disease and rheumatoid arthritis, indicating it is generally well-tolerated.

Research has shown that common side effects of infliximab include mild issues like headaches and stomach pain. Some individuals might experience more serious side effects, such as infections, due to infliximab's potential to weaken the immune system, though these serious effects are less common.

Prednisone, a steroid, is often used to reduce swelling and inflammation and has a long history of use. Typical side effects include increased hunger, mood changes, and trouble sleeping. Long-term use can lead to more serious effects like high blood pressure or weakened bones.

Most treatments for acute kidney injury primarily focus on supportive care, like managing fluid balance and addressing underlying causes. Infliximab is unique because it targets inflammation in a novel way, acting as a monoclonal antibody that specifically blocks tumor necrosis factor-alpha (TNF-alpha), a key player in inflammation. Researchers are excited about infliximab because, unlike standard care, it offers a targeted approach that could potentially reduce inflammation more effectively and improve kidney function faster. This targeted action could make a significant difference in outcomes for patients with this condition.

Research has shown that infliximab can protect the kidneys by reducing oxidative stress, which harms cells. Specifically, studies have found that infliximab lowers levels of harmful substances in the blood, such as urea and creatinine, which indicate kidney damage. Infliximab also reduces inflammation, a common issue in sudden kidney problems. In this trial, some participants will receive infliximab alongside prednisone. However, infliximab may increase the risk of infections. Overall, infliximab appears promising for kidney protection, but some risks require consideration.⁶⁷⁸⁹¹⁰